BNP Paribas Financial Markets
CADL icon

BNP Paribas Financial Markets’s Candel Therapeutics CADL Stock Holding History

BNP Paribas Financial Markets’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$114K Buy
11,046
+517
+5% +$3.9K ﹤0.01% 4479
2026
Q1 		$51.6K Buy
10,529
+594
+6% +$3.23K ﹤0.01% 4679
2025
Q4 		$56.1K Buy
9,935
+2,034
+26% +$10.9K ﹤0.01% 4629
2025
Q3 		$40.3K Buy
7,901
+4,439
+128% +$25.6K ﹤0.01% 4688
2025
Q2 		$17.5K Buy
3,462
+2,097
+154% +$10.8K ﹤0.01% 4661
2025
Q1 		$7.71K Sell
1,365
-2,069
-60% -$16.9K ﹤0.01% 4784
2024
Q4 		$29.8K Buy
+3,434
New +$20.3K ﹤0.01% 4608
2022
Q4 		– Sell
-410
Closed -$1.29K – 4133
2022
Q3 		$1.29K Buy
+410
New +$1.39K ﹤0.01% 4400

Other funds holding CADL

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $617M AUM 69.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BNP Paribas Financial Markets's CADL Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Candel Therapeutics (CADL) stake by 4.9% in Q2 2026, buying an estimated $3.9K and bringing the position to 11,046 shares worth $114K. The position accounts for ﹤0.01% of the portfolio, ranked #4479.

BNP Paribas Financial Markets first reported a position in CADL in Q3 2022 and has held it in 8 quarters since. 128 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • BNP Paribas Financial Markets held 11,046 shares of Candel Therapeutics worth $114K as of Q2 2026.
  • BNP Paribas Financial Markets bought 517 Candel Therapeutics shares in Q2 2026, an estimated $3.9K.
  • Candel Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4479 holding.
  • BNP Paribas Financial Markets first reported a position in Candel Therapeutics in Q3 2022 and has held it in 8 quarters since.
  • 128 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.